Ivonescimab's OS benefit holds up in Western patients, with HARMONi-2 data reinforcing its efficacy profile
SMMT sits 52% above its 52-week low of $12.07.
Summary
At WCLC 2026, Summit presented updated HARMONi data showing consistent overall survival benefit in Western and Asian patients, along with full HARMONi-2 results demonstrating ivonescimab beat pembrolizumab on overall survival.
Key Events · Product Development and Regulatory · SMMT
-
HARMONi OS Benefit Consistent Across Regions
The updated June 2026 analysis shows a global OS hazard ratio of 0.76 (95% CI: 0.61–0.95; nominal p=0.0151), with the Western patient subgroup HR improving to 0.76 (95% CI: 0.52–1.10) from 0.98 at the primary analysis.
-
Western Patient Follow-Up Extended
Median follow-up for Western patients reached 23.2 months, up from 9.2 months at the April 2025 primary analysis, allowing the survival benefit to emerge consistently with Asian patients.
-
HARMONi-2 Full OS Results Presented
Ivonescimab monotherapy showed median OS of 30.8 months vs 22.6 months for pembrolizumab (HR 0.73; 95% CI: 0.57–0.95; p=0.009), with benefit across PD-L1 expression levels and histologies.
-
PDUFA Date Approaching
Summit's BLA for ivonescimab in EGFR-mutated NSCLC has a PDUFA goal action date of November 14, 2026, with these data reinforcing the regulatory case.
Analysis · SMMT · Life Sciences
With longer follow-up, the updated HARMONi data now show a consistent overall survival benefit for ivonescimab plus chemotherapy across both Western and Asian patients. The Western subgroup hazard ratio improved to 0.76 from 0.98 at the primary analysis, directly addressing a key regulatory concern about regional consistency ahead of the November 14, 2026 PDUFA date. Full HARMONi-2 results, which demonstrate a 27% reduction in death risk versus pembrolizumab, further strengthen the case for ivonescimab's differentiated profile.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMMT was trading at $18.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.7B. The 52-week trading range was $12.07 to $29.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.